Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?

This analysis showed that trastuzumab with adjuvant hypo-RT for patients with breast cancer was generally well-tolerated in routine clinical practice. A longer follow-up will be necessary to assess late cardiac toxicity.